Foldrx Pharms Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for FOLDRX PHARMS, and what generic alternatives to FOLDRX PHARMS drugs are available?
FOLDRX PHARMS has two approved drugs.
There are five US patents protecting FOLDRX PHARMS drugs.
There are fifty-four patent family members on FOLDRX PHARMS drugs in twenty-eight countries and fourteen supplementary protection certificates in thirteen countries.
Summary for Foldrx Pharms
| International Patents: | 54 |
| US Patents: | 5 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Foldrx Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | 8,653,119 | See Plans and Pricing | See Plans and Pricing | ||||
| Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | 7,214,696 | See Plans and Pricing | See Plans and Pricing | ||||
| Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | 8,168,663 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Foldrx Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2016065042 | See Plans and Pricing |
| Canada | 2903194 | See Plans and Pricing |
| Australia | 2015313875 | See Plans and Pricing |
| Brazil | 0317463 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Foldrx Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1587821 | CR 2012 00006 | Denmark | See Plans and Pricing | PRODUCT NAME: TAFAMIDIS (SOM MEGLUMIN); REG. NO/DATE: EU/1/11/717/001 20111116 |
| 1587821 | 12C0008 | France | See Plans and Pricing | PRODUCT NAME: TAFAMIDIS OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/11/717/001 20111118 |
| 1587821 | 91935 | Luxembourg | See Plans and Pricing | 91935, EXPIRES: 20261116 |
| 1587821 | 382 | Finland | See Plans and Pricing | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
